Dendreon, Geron jobs cut after Valeant, Janssen deals
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals pulled Dendreon out of bankruptcy by acquiring the troubled prostate cancer immunotherapy company, and Johnson & Johnson's Janssen Biotech subsidiary pumped much-needed cash into Geron with a drug development partnership, but because of those deals 95 people at Dendreon and Geron are losing their jobs.
You may also be interested in...
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.